AD\u00a0is a chronic inflammatory skin disease marked by pruritus, eczema, and, in moderate to severe patients, frequent relapse. Standard\u00a0AD\u00a0treatments aim to protect the skin barrier through moisturization and to reduce inflammation and pruritus. Topical corticosteroids and topical immunomodulators are the mainstays of\u00a0AD\u00a0treatment in patients whose disease is not adequately controlled by emollients alone. Additionally, ultraviolet light and systemic immunomodulators are used to treat topical-refractory\u00a0AD. Topical therapies are often effective for mild disease; however, more-effective therapies for severe\u00a0AD\u00a0are sorely needed. The\u00a0AD\u00a0pipeline is burgeoning, owing to the unmet need and commercial opportunity for improved\u00a0AD\u00a0therapeutics; this is highlighted by the recent launch of Pfizer\u2019s topical Eucrisa (crisaborole) and Sanofi\/Regeneron\u2019s Dupixent (dupilumab), as well as the large number of diverse mid- to late-phase programs (e.g.,\u00a0IL-13 inhibitors,\u00a0JAKinhibitors,\u00a0IL-31 inhibitors). This report provides a comprehensive analysis of current\u00a0ADmanagement, the impact of recent market entrants, lingering unmet needs, and the clinical and commercial potential of emerging drugs.<\/p>\n
QUESTIONS ANSWERED<\/strong><\/p>\n What are the sizes of key patient subpopulations and how will they change by 2026? How well are these populations served by current\u00a0AD\u00a0therapies?<\/p>\n How will the launches of Pfizer\u2019s Eucrisa, Sanofi\/Regeneron\u2019s Dupixent, and emerging programs alter the\u00a0AD\u00a0treatment landscape?<\/p>\n What emerging therapies are in development for\u00a0AD? Which are best poised to achieve commercial success, and why?<\/p>\n Where are the key unmet needs and commercial opportunities in the\u00a0AD\u00a0space? To what extent will emerging therapies address these needs?<\/p>\n PRODUCT DESCRIPTION<\/strong><\/p>\n Disease Landscape & Forecast: Comprehensive market intelligence providing world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed\u00a0primary and secondary research.<\/p>\n","protected":false},"template":"","class_list":["post-390795","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-date-890"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390795","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390795\/revisions"}],"predecessor-version":[{"id":576772,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/390795\/revisions\/576772"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=390795"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}